^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Clinical efficacy and safety of apatinib as maintenance treatment in patients with advanced oesophageal squamous cell carcinoma

Published date:
10/29/2020
Excerpt:
We selected 46 patients with advanced oesophageal squamous cell carcinoma...The oral treatment of apatinib in the VEGFR-2 and NF-kB positive groups was better than that in the negative groups. The partial remission rate of patients was 26.09%, and the disease control rate was 67.39%....The median progression-free survival was 3.7 months and the median overall survival was 7.2 months.
DOI:
10.1080/17512433.2020.1844004